Remove Bioinformatics Remove Genome Remove Trials
article thumbnail

How Will Ultima Genomics and Genome Insight Make WGS Affordable?

XTalks

The application of whole genome sequencing (WGS) to derive a more complete understanding of cancer has been a central goal of cancer researchers even before the first human genome was decoded in 2003. Ultima Genomics has already partnered with other leading biotech startups.

Genome 97
article thumbnail

The future of genomic medicine: can it fulfil its promises?

pharmaphorum

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. I saw this, in particular, with the finishing of the human genome,” says Charlie. “At In reality, finishing the human genome was the first step of what is a long journey.”.

Genome 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CancerVar: A New Bioinformatics Tool Developed for Clinical Interpretation of Cancer Mutations

XTalks

On Saturday, researchers at the Children’s Hospital of Philadelphia (CHOP) have announced that they developed and launched a new bioinformatics software tool called CancerVar (cancer variant interpretation). XTALKS WEBINAR: Harnessing Artificial Intelligence for Higher Quality Data in Preclinical Trials and Translational Research.

article thumbnail

Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s

pharmaphorum

A software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in their earliest stages is being tested in a five-year trial involving thousands of patients.

Trials 78
article thumbnail

Oncotarget: The comprehensive genomic profiling test, GEM ExTra®

Scienmag

Proprietary bioinformatics, paired with comprehensive clinical curation results in reporting that defines clinically actionable, FDA-approved, and clinical trial drug options for the management of the patient’s cancer.

Genome 41
article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

Essentially, the collaboration brought together both “the right expertise and the right technology”, opening up myriad possibilities for targeting GPCRs within the human genome. It also bodes well for improving clinical trial success rates. A notable issue with clinical trials is the homogeneity of the patient database.

article thumbnail

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

These tumor-derived entities are used to derive genomic and proteomic data. Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials.